Not a good buy right now for an impatient investor: there’s no proprietary buy signal today and the stock is weak on the day (-3.75%) in a down market.
Technicals are mildly constructive (bullish MA stack), but momentum is not strong (MACD positive but contracting) and price is below the pivot (1.175), suggesting you’re not getting a clean immediate breakout setup.
Fundamentals remain pressured (losses widening, negative gross margin), and the latest news points to potential dilution/structure changes even if liquidity improves.
Gross margin: -48.8% (down -7.31% YoY) — still strongly negative, indicating poor unit economics at current scale.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Most recent update: 2025-12-10 Ascendiant reiterated Buy and raised price target to $8.25 from $8 after Q3 results.
Wall Street pro view (pros): expectation of high growth and potential Medicare coverage in 2026 as a major upside catalyst.
Wall Street pro view (cons): the current financial profile (widening losses/negative margin) implies execution and funding/dilution risk until reimbursement and scale materially improve.
Overall: bullish analyst stance, but it’s a longer-duration thesis rather than an “immediate upside” setup.
Wall Street analysts forecast LUCD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUCD is 4.05 USD with a low forecast of 3 USD and a high forecast of 8.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast LUCD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUCD is 4.05 USD with a low forecast of 3 USD and a high forecast of 8.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.150
Low
3
Averages
4.05
High
8.25
Current: 1.150
Low
3
Averages
4.05
High
8.25
Ascendiant
Edward Woo
Buy
maintain
$8
AI Analysis
2025-12-10
Reason
Ascendiant
Edward Woo
Price Target
$8
AI Analysis
2025-12-10
maintain
Buy
Reason
Ascendiant analyst Edward Woo raised the firm's price target on Lucid Diagnostics to $8.25 from $8 and keeps a Buy rating on the shares following the company's Q3 report issued on November 12. Expected high growth and Medicare coverage in 2026 should drive the stock "much higher," the analyst contends.
BTIG
Mark Massaro
Buy
maintain
$2
2025-09-05
Reason
BTIG
Mark Massaro
Price Target
$2
2025-09-05
maintain
Buy
Reason
BTIG analyst Mark Massaro raised the firm's price target on Lucid Diagnostics to $2.50 from $2 and keeps a Buy rating on the shares. Attending the CMS meeting to discuss the merits of Medicare coverage for Lucid's EsoGuard test, the firm heard "unanimously positive statements" from all clinicians supporting the "obvious use case" for EsoGuard, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LUCD
